Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

Phase 1

• Conditions: Androgenetic alopecia; Therapeutic area: Diseases [C] - Hormonal diseases [C19]

• Registration Number: EUCTR2013-002740-85-ES
• Lead Sponsor: BTI BIOTECHNOLOGY INSTITUTE IMASD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11-12
• Last Update Posted: 22 January 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

* Androgenetic alopecia according to the following scales:

Men: Hamilton/Norwood Scale: grades II-VI
Women: Ludwig Scale grades I-II.

* Possibility of follow-up during the study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 24
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

?No androgenetic alopecia
?Telogen and anagen effluvium
?Active inflammation or infection in the intervention area
?Presence of active systemic infections.
?Background of cancerous or precancerous lesions.
?Background of connective or rheumatic diseases.
?Suffering from any serious blood disorders.
?To have undergone treatments for alopecia in the previous 6 months.
?Previous hair implants
?Intake of drugs that affect hair loss.
?Be undergoing immunosuppressive therapy and/or anticoagulants.
?Known intolerance to mesotherapy.
?Taking contraceptives containing cyproterone acetate.
?Pregnancy
?In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified